Drug Trial Radar · NCT01066962
Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve Subjects
Last checked: Nov 19, 2026Latest source record: Nov 6, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
800
Actual
Start
Aug 2010
Primary completion
Oct 2013
Study completion Oct 2013
Sponsor
- Lead sponsor
- ANRS, Emerging Infectious DiseasesGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- Collaborators
- NEAT - European AIDS Treatment Network
- First posted
- Feb 10, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The triple therapy darunavir/r + tenofovir/emtricitabine is likely to become a relevant first-line treatment option in the years to come. The dual combination of boosted darunavir + raltegravir is an innovative treatment option that combines two potent new antiretroviral drugs, one of which belongs to a new drug class (integrase inhibitor). The expected efficacy profile of this combination is promising. Moreover, this combination might have a better tolerance profile and has the advantage of sparing the NRTI class. In the context of tenofovir/emtricitabine currently being a reference backbone in first-line antiretroviral regimens, we hypothesise that, in combination with darunavir/r, raltegravir may be an alternative option if its efficacy is non-inferior to tenofovir/emtricitabine.
Conditions
- HIV Infections
Interventions
darunavir/ritonavir QD + raltegravir BIDDrug
darunavir 800 mg, i.e. 2 tablets of 400 mg once daily (QD) ritonavir 100 mg, 1 tablet once daily (QD) raltegravir 400 mg, 1 tablet twice daily (BID)
darunavir/r QD + tenofovir/emtricitabine QD (fixed dose combination)Drug
darunavir 800 mg, i.e. 2 tablets of 400 mg once daily (QD) ritonavir 100 mg, 1 tablet once daily (QD) tenofovir/emtricitabine 245/200 mg, fixed dose combination, 1 tablet once daily (QD)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to virologic or clinical failure, as the first occurrence of one of six protocol-defined componentsTime frame: minimum 2 years
Locations
77 sites in 15 countries. Site status is shown where the registry gives one.
Allgemeines Krankenhaus der Stadt Wien
Vienna, Austria
Otto Wagner Spital mit Pflegezentrum
Vienna, Austria
ITZ Antwerpen
Antwerp, Belgium
CHU Saint Pierre
Brussels, Belgium
UZ Gent
Ghent, Belgium
Rigshospitalet
Copenhagen, Denmark
Hvidovre Hospital
Hvidovre, Denmark
Hôpital Pellegrin
Bordeaux, France
Hôpital Saint André
Bordeaux, France
Hôpital Henri Mondor
Créteil, France
Hôpital du Bocage
Dijon, France
Hôpital Pierre Zobda-Quitman
Fort de France, France
CHD de la Roche sur Yon
La Roche-sur-Yon, France
Hôpital Bicêtre
Le Kremlin-Bicêtre, France
Hôpital Gui de Chauliac
Montpellier, France
Hôpital de l'Hôtel Dieu
Nantes, France
Hôpital Bichat
Paris, France
Hôpital Européen Georges Pompidou (HEGP)
Paris, France
Hôpital La Pitié Salpétrière
Paris, France
Hôpital Saint Antoine
Paris, France
Hôpital Saint Louis
Paris, France
Hôpital Pontchaillou
Rennes, France
Hôpital Foch
Suresnes, France
Hôpital Purpan
Toulouse, France
Hôpital Gustave Dron
Tourcoing, France
Gemeinschaftspraxis Jessen-Jessen-Stein
Berlin, Germany
Med. Universitätsklinik I
Bonn, Germany
Universitätsklinik Köln
Cologne, Germany
Universitätsklinikum Essen
Essen, Germany
Klinikum der Johann Wolfgang Goethe Universität
Frankfurt, Germany
Asklepios-Klinik St. Georg
Hamburg, Germany
ICH study centre
Hamburg, Germany
Medizinische Hochschule Hannover
Hanover, Germany
Attikon University Hospital
Athens, Greece
Evaggelismos General Hospital
Athens, Greece
Laikon General Hospital
Athens, Greece
Saint Laszlo Hospital
Budapest, Hungary
Mater Misericordiae
Dublin, Ireland
St James's Hospital
Dublin, Ireland
University of Brescia
Brescia, Italy
Showing 40 of 77 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.